Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s p
FORTIFY, a Phase 1b indication expansion trial of PLN-101095, continues strong enrollment Pliant’s p